Lantheus Holdings Inc (NASDAQ:LNTH) stock price target increased to $9.50, issued a research note today by Zacks Investment Research
- Updated: October 17, 2016
In a report released on 10/18/2016 Zacks Investment Research increased the stock price target of Lantheus Holdings Inc (NASDAQ:LNTH) to $9.50 indicating a possible upside of 0.23%.
Previously on 10/12/2016, Zacks Investment Research reported on Lantheus Holdings Inc (NASDAQ:LNTH) increased the target price from $0.00 to $9.00. At the time, this indicated a possible upside of 0.12%.
Yesterday Lantheus Holdings Inc (NASDAQ:LNTH) traded 9.74% higher at $7.70. The company’s 50-day moving average is $8.49 and its 200-day moving average is $4.75. The last closing price is up 77.91% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 423,421 shares of the stock traded hands, down from an average trading volume of 467,929
See Chart Below
Lantheus Holdings Inc has a 52 week low of $1.76 and a 52 week high of $10.10 with a P/E ratio of 9.54 The company’s market cap is currently $0.
General Information About Lantheus Holdings Inc (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company's portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company's Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company's imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.